Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)

NCT00626444 | Terminated Phase 2 Results DMC

• 2 other identifiers: 07U.21JT 1201
• Study Type: interventional
• Target: 2
• Locations: 1 country
• Sites: 1

Brief Summary

Eligible candidates will be adults with aggressive or very aggressive NHL (WHO classification diagnosis confirmed by histological tumor examination). Patients must have failed one or more prior NHL chemotherapy or antibody therapy with curative intent, and the disease must not have progressed within 60 days of last therapy. In addition, patients must not be candidates for potentially curative therapy, such as HSCT, or they must have refused these alternative therapies. Full inclusion/exclusion criteria are available. History and physical examination, and laboratory and imaging analyses will be done within 14 days prior to registration. Intravenous ascorbic acid will be given in a dose based on the plasma vitamin C level to reach a level in the range of 300 to 350 mg/dL. Vitamin C infusions will be given three times a week on a schedule that allows at least 24 hours between each infusion, for a total of ten weeks (30 infusions). If disease progression occurs before or at the ten week assessment, then we discontinue protocol, based on futility. Toxicity and adverse events also will result in immediate discontinuation (details available in full protocol). If there is lack of disease progression or disease improvement, proceed and reassess again at 10 week intervals, for a total of three 10 week intervals. Initial criteria are based upon the criteria from the International Workshop to Standardize Criteria for Non-Hodgkin's Lymphoma (Cheson et al., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma, Journal of Clinical Oncology, 1999, Vol. 17, No4, 1244-1253); response for this study will utilize PET in accordance with revised criteria (Cheson et al. Revised response criteria for malignant lymphoma. J of Clin Oncol 2007; 25(5): 579-586). We select 20 patients as an appropriate study size to evaluate a true response rate to therapy, compared to just the observed response.

Conditions

Non-Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

• Progression-free Survival

  10 weeks

Secondary Outcomes (1)

• Duration of Response

  10 weeks

Study Arms (1)

1

EXPERIMENTAL

Intravenous vitamin C

Drug: Intravenous vitamin C

Interventions

Intravenous vitamin C DRUG

Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age greater than 18 years old
• Aggressive or very aggressive NHL
• Failed one or more therapies
• Patients must not have progressed within 60 days of last therapy
• Not received allogeneic stem cell transplant
• No reasonable standard therapeutic options available
• Glucose 6 phosphate dehydrogenase status normal
• ECOG performance status 0-2
• Normal creatinine and transaminase
• Women of child-bearing potential confirm negative pregnancy test

You may not qualify if:

• Significant co-morbid disorders
• Significant psychiatric symptoms
• Smoking
• Excessive alcohol or drug use
• Enrollment in other experimental therapy
• Active infection
• Patients experiencing ongoing response to recent treatments
• Patients who have received chemotherapy within 30 days or biological therapy within 6 weeks

Sponsors & Collaborators

• Sidney Kimmel Cancer Center at Thomas Jefferson University: lead

Study Sites (1)

Jefferson-Myrna Brind Center of Integrative Medicine

Philadelphia, Pennsylvania, 19107, United States

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Limitations and Caveats

Study was terminated due to poor accrual. No reportable data has been collected for any of the specified outcome measures.

Results Point of Contact

• Title: Daniel Monti, MD
• Organization: Thomas Jefferson University

Daniel.Monti@jefferson.edu

215-955-4410

Study Officials

• Daniel Monti, MD

  Faculty Member

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2008
• First Posted: February 29, 2008
• Study Start: February 1, 2008
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: May 16, 2025
• Results First Posted: December 10, 2014

Record last verified: 2025-05

Locations

US (1)